LAS VEGAS, May 15, 2018 (GLOBE NEWSWIRE) — BioAdaptives, Inc. (OTC PINK:BDPT) announced Dr. James Rouse has been appointed to the board of Directors and accepted the position of President. He will start serving in both roles effective immediately. Dr. James, as he is fondly known, is a functional medicine doctor, primary care trained clinician, an expert in the field of regenerative medicine and epigenetics. He is an award-winning author of 13 books, as well as a media personality, and international speaker and coach.
Kim D. Southworth, Chairman and CEO said, “We are excited Dr. James will be guiding the Company to evolve from a research development entity to an epigenetics business. The new Living Longevity Lab, founded by Dr. James, will deliver his high impact, life-changing, educational philosophy. BioAdaptives will continuously be expanding through the ever-evolving Living Longevity Lab. Dr. James will also build on the existing BioAdaptives’ research regarding stem cells, telomeres, and nootropics, to bring to market a unique, highly effective, proven product line.”
Southworth added, “Dr. James also successfully founded and built four companies in Media, Consumer Package Goods, and Nutraceuticals, all of which have gone on to generate millions of dollars in sales. BioAdaptives looks forward to a profitable and inspiring future under Dr. James’ direction.”
Dr. James commented, “Accepting the role of President and Founder of Living Longevity Lab is an honor and joy that I hold with unbridled enthusiasm and esteemed responsibility. Creating the Living Longevity Lab is an expression of my passion for community and human potential and performance. We have a unique and significant opportunity to bring our empowered mission and vision to a worldwide community that embraces the science of proactive lifestyle and the efficacy of research-driven products. Our dedicated and gifted team is aligned and poised to bring our love for serving and inspiring to lead an evolution and revolution in well-being to millions of seekers of ever-expanding longevity, vitality and life fulfillment.”
About BioAdaptives, Inc.
BioAdaptives, Inc. is a public company trading on OTC: PINK under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for human and animal consumption.
SAFE HARBOR ACT
Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc. and its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc.’s filings with the Securities and Exchange Commission.
A video accompanying this press release is available at:
SOURCE: BioAdaptives, Inc.